Focus: GSK is a London-based Big Pharma company with 70,000 employees specializing in small molecules, vaccines, and biologics across vaccines, infectious disease, HIV/AIDS, oncology, and immunology. The company operates at peak scale with a diversified therapeutic portfolio.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Hot — 937 jobs added in 30d
Net +220 (937 new, 717 removed). Aggressive expansion phase.
2 recent layoff filings (12 mo) — 300 affected
Source: state DOL filings via Big Local News
GSK is a stable Big Pharma employer with unmatched commercial reach, but the massive patent cliff and modest pipeline create restructuring risk over the next 5-7 years; best for commercial, manufacturing, or medical affairs professionals seeking security in established markets.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Accounts for 44% of company revenue and represents the single largest cliff risk; LOE in 2031 will trigger significant commercial restructuring.
Help build intelligence for GSK
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from GSK's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Second largest revenue generator; same LOE date as TRELEGY creates compounded cliff risk and market transition challenge.
Part of respiratory franchise that dominates GSK portfolio; third cliff event in short window increases job displacement risk.
First major revenue cliff (2027), signaling early erosion of respiratory franchise profitability.
Inhaled corticosteroid losing exclusivity first (August 2026); sets precedent for respiratory portfolio vulnerability.
181 discontinued, 48 duplicate formulations not shown
+18 more products with revenue data
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
+35 more products
Source: state DOL filings, aggregated via Big Local News
No immediate operational red flags (FDA warnings, WARN Act filings), but severe patent cliff creates elevated restructuring risk beginning 2026.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo